SRR8613702
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.460
- APICAL_SURFACE+0.410
- HEDGEHOG_SIGNALING+0.400
- ESTROGEN_RESPONSE_EARLY+0.260
- INTERFERON_GAMMA_RESPONSE+0.210
- PANCREAS_BETA_CELLS+0.160
- KRAS_SIGNALING_DN+0.150
- ESTROGEN_RESPONSE_LATE+0.140
- APICAL_JUNCTION+0.120
- MYOGENESIS+0.120
Top 10 suppressed
- MYC_TARGETS_V1-0.560
- E2F_TARGETS-0.470
- OXIDATIVE_PHOSPHORYLATION-0.430
- MTORC1_SIGNALING-0.420
- MYC_TARGETS_V2-0.370
- G2M_CHECKPOINT-0.350
- ALLOGRAFT_REJECTION-0.340
- CHOLESTEROL_HOMEOSTASIS-0.320
- PROTEIN_SECRETION-0.320
- FATTY_ACID_METABOLISM-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03890 | — | cohortA1 | 0.861 |
| 2 | MNG1295 | — | — | 0.837 |
| 3 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.819 |
| 4 | SRR25617906 | — | B | 0.819 |
| 5 | C3N-02146 | — | cohortA1 | 0.807 |
| 6 | e32633c0-5ccc-47a9-bd67-60d3c022dfc9 | — | — | 0.806 |
| 7 | MNG690 | — | — | 0.802 |
| 8 | SRR1489779 | GTEX | — | 0.802 |
| 9 | MNG661 | — | — | 0.796 |
| 10 | BS_4W68NV3M | Med | Medulloblastoma | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.070 | Inavolisib | — uncovered |